Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NewAmsterdam Pharma Company ( (NAMS) ) has shared an update.
On August 12, 2025, NewAmsterdam Pharma’s subsidiary entered into a Supply Agreement with A. Menarini International Licensing S.A. to supply obicetrapib monotherapy and combination drug products. The agreement outlines NewAmsterdam Pharma as the exclusive supplier initially, with plans to transfer manufacturing to Menarini or a third party, impacting the company’s operational dynamics and industry positioning.
The most recent analyst rating on (NAMS) stock is a Hold with a $23.60 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.
Spark’s Take on NAMS Stock
According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.
NewAmsterdam Pharma’s overall stock score is driven by strong technical momentum and positive corporate events, particularly the promising Phase 3 trial results. However, the score is moderated by financial performance challenges, including lack of profitability and negative cash flows. The valuation remains a concern due to the negative P/E ratio, but the company’s growth potential in Alzheimer’s and cardiovascular treatments offers a compelling long-term opportunity.
To see Spark’s full report on NAMS stock, click here.
More about NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V. operates in the pharmaceutical industry, focusing on the development and supply of drug products, including obicetrapib monotherapy and obicetrapib and ezetimibe fixed-dose combinations.
Average Trading Volume: 853,897
Technical Sentiment Signal: Buy
Current Market Cap: $2.83B
For detailed information about NAMS stock, go to TipRanks’ Stock Analysis page.